Xencor (XNCR) Interest Expenses (2013 - 2026)
Xencor's (XNCR) quarterly Interest Expenses came in at $92.0 million in Q1 2026, up 962.15% year-on-year from $8.7 million in Q1 2025, and up 474.61% on a QoQ basis from -$24.6 million in Q4 2025.
Xencor (XNCR) Interest Expenses (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Interest Expenses data on file, last reported at $92.0 million in Q1 2026.
- On a quarterly basis, Interest Expenses rose 962.15% year-over-year to $92.0 million in Q1 2026; TTM through Mar 2026 was $92.0 million, a 57.43% increase from a year earlier, with the FY2025 full-year figure at $94.6 million, down 58.37% from the prior year.
- Interest Expenses for Q1 2026 stood at $92.0 million, up from -$24.6 million in the prior quarter.
- Over the last five years, Interest Expenses for XNCR reached as high as $103.5 million in Q3 2024 and fell as low as -$24.6 million in Q4 2025.
- Historically, Interest Expenses has averaged $33.7 million across 5 years, with a median of $27.1 million in 2022.
- Across the five-year window, Interest Expenses jumped 1236.46% in 2024 and tumbled 172.34% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $956000.0 in 2022, then surged by 543.93% to $6.2 million in 2023, then soared by 451.72% to $34.0 million in 2024, then tumbled by 172.34% to -$24.6 million in 2025, then surged by 474.61% to $92.0 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $92.0 million in Q1 2026, -$24.6 million in Q4 2025, and $97.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | 92.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 92.04 Mn |
| Mar 31, 2026 | 92.04 Mn |
| Dec 31, 2025 | -24.57 Mn |
| Dec 31, 2025 | -24.57 Mn |
| Sep 30, 2025 | 97.09 Mn |
| Sep 30, 2025 | 97.09 Mn |
| Jun 30, 2025 | 96.37 Mn |
| Jun 30, 2025 | 96.37 Mn |
| Mar 31, 2025 | 8.67 Mn |
| Mar 31, 2025 | 8.67 Mn |
| Dec 31, 2024 | 33.96 Mn |
| Dec 31, 2024 | 33.96 Mn |
| Sep 30, 2024 | 103.47 Mn |
| Sep 30, 2024 | 103.47 Mn |
| Jun 30, 2024 | 33.45 Mn |
| Jun 30, 2024 | 33.45 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Mar 31, 2024 | 9.68 Mn |
| Dec 31, 2023 | 6.16 Mn |
| Dec 31, 2023 | 6.16 Mn |